Solving Cell & Gene Therapy Capacity Shortages: End-To-End CDMO Services
The cell and gene therapy (C>) market is experiencing an explosion of growth with record-breaking financing, major clinical milestones, and commercial progress creating seemingly vast opportunities. An enormous pipeline of treatments in the market has created seemingly endless possibilities. However, this explosive growth results in one issue set to derail the promise of this sector – manufacturing capacity shortages.
Creating new manufacturing capacity requires investments, lead time and technical expertise. It also requires finding the right CDMO with a global footprint, large-scale capacities and resources, and technical expertise in developing and bringing treatments to market.
Our Global BD Head for Cell & Gene Therapy, Ramin Baghirzade, shares his insights into what it takes to help solve this industry-wide capacity issue. He also details why we are one of the only global CDMOs uniquely positioned to help immediately produce new C> products.
Get unlimited access to:
Enter your credentials below to log in. Not yet a member of Bioprocess Online? Subscribe today.